Comparative Efficacy and Safety of Biosimilar Bevacizumab (Stivant®) versus Reference Product (Avastin®) in Prethreshold Type I Retinopathy of Prematurity

Purpose: To compare the efficacy and safety of Stivant® (biosimilar bevacizumab, CinnaGen, Iran) to Avastin® (innovator bevacizumab, Genentech, South San Francisco, CA) in premature infants with prethreshold type I retinopathy of prematurity (ROP). Methods: Preterm infants with bilateral prethreshol...

Descripció completa

Dades bibliogràfiques

Autors principals:	Mojtaba Abrishami, Zohreh Golmohammadi, Nasser Shoeibi, Mohammad-Reza Ansari-Astaneh, Mehdi Sakhayi, Majid Abrishami, Seyedeh Maryam Hosseini, Elham Bakhtiari, Mehrdad Motamed Shariati
Format:	Artigo
Idioma:	Inglês
Publicat:	Wolters Kluwer Medknow Publications 2024-10-01
Col·lecció:	Journal of Current Ophthalmology
Matèries:	avastin bevacizumab efficacy retinopathy of prematurity safety stivant
Accés en línia:	https://journals.lww.com/10.4103/joco.joco_178_24
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!